The Union has been leading the way in knowledge and research sharing around COVID-19 and lung health, including a powerful webinar series, publishing guidance, briefings, journal articles, and a set of frequently asked questions.
FAQs on COVID-19 and lung health
The Union has published a set of frequently asked questions regarding COVID-19 and lung health, focusing on its impact on TB services and the people undergoing TB treatment, and guidance to maintain quality care throughout this period, as well as recommendations and guidance for healthcare workers treating smokers with COVID-19.
Webinar series: COVID-19 and lung health
The COVID-19 pandemic is perhaps the greatest healthcare challenge of a generation. The Union, in collaboration with its global community of members, is pleased to launch an open-access webinar series on COVID-19 and its intersection with tuberculosis (TB), tobacco control, lung disease and more.
See our other webinars here
The Union statement on the importance of TB in Universal Health Coverage
Today, 29 April 2019, the President of the United Nations (UN) General Assembly, with the support of the World Health Organization (WHO…
Health Organisations Call on The Walt Disney Company to Terminate Vice Media Partnership with Philip Morris International
A coalition of eight national and international health organisations today urged The Walt Disney Company (Disney) to require its partner…
“This is a problem we can solve. We just need people to care.” TB survivors meet with US politicians to push for more funding to end TB
Sixteen tuberculosis (TB) survivors met with leaders on Capitol Hill in Washington, DC, to share their experiences with those who have…
Experts call for tax rise to address growing NCD burden
Today the Task Force on Fiscal Policy for Health has published “Health Taxes to Save Lives”, calling on countries to significantly raise…
Stream clinical trial results prove that a nine-month treatment regimen for MDR-TB is as effective as the 20-month regimen
Final results released today in the New England Journal of Medicine from Stage 1 of the STREAM randomised clinical trial show that a 9-…
Union response to release of final results from Stage 1 of the STREAM trial
In response to the publication of final results from Stage 1 of the STREAM trial, Dr Paula I Fujiwara, Scientific Director, The Union,…
COVID official guidance
Read official guidance from The Union and our partner organisations on the latest guidance on COVID-19.
IJTLD fast-tracked articles
In order to share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking accepted articles from the International Journal of Tuberculosis and Lung Disease (IJTLD) regarding COVID-19 and publishing them in full on our website, prior to their publication in the Journal.
See a complete list of all of our fast-tracked articles here.
The Union statement on the importance of TB in Universal Health Coverage
Today, 29 April 2019, the President of the United Nations (UN) General Assembly, with the support of the World Health Organization (WHO…
Health Organisations Call on The Walt Disney Company to Terminate Vice Media Partnership with Philip Morris International
A coalition of eight national and international health organisations today urged The Walt Disney Company (Disney) to require its partner…
“This is a problem we can solve. We just need people to care.” TB survivors meet with US politicians to push for more funding to end TB
Sixteen tuberculosis (TB) survivors met with leaders on Capitol Hill in Washington, DC, to share their experiences with those who have…
Experts call for tax rise to address growing NCD burden
Today the Task Force on Fiscal Policy for Health has published “Health Taxes to Save Lives”, calling on countries to significantly raise…
Stream clinical trial results prove that a nine-month treatment regimen for MDR-TB is as effective as the 20-month regimen
Final results released today in the New England Journal of Medicine from Stage 1 of the STREAM randomised clinical trial show that a 9-…
Union response to release of final results from Stage 1 of the STREAM trial
In response to the publication of final results from Stage 1 of the STREAM trial, Dr Paula I Fujiwara, Scientific Director, The Union,…
The latest Union news about COVID-19
The Union statement on the importance of TB in Universal Health Coverage
Today, 29 April 2019, the President of the United Nations (UN) General Assembly, with the support of the World Health Organization (WHO…
Health Organisations Call on The Walt Disney Company to Terminate Vice Media Partnership with Philip Morris International
A coalition of eight national and international health organisations today urged The Walt Disney Company (Disney) to require its partner…
“This is a problem we can solve. We just need people to care.” TB survivors meet with US politicians to push for more funding to end TB
Sixteen tuberculosis (TB) survivors met with leaders on Capitol Hill in Washington, DC, to share their experiences with those who have…
Experts call for tax rise to address growing NCD burden
Today the Task Force on Fiscal Policy for Health has published “Health Taxes to Save Lives”, calling on countries to significantly raise…
Stream clinical trial results prove that a nine-month treatment regimen for MDR-TB is as effective as the 20-month regimen
Final results released today in the New England Journal of Medicine from Stage 1 of the STREAM randomised clinical trial show that a 9-…
Union response to release of final results from Stage 1 of the STREAM trial
In response to the publication of final results from Stage 1 of the STREAM trial, Dr Paula I Fujiwara, Scientific Director, The Union,…
Partner sponsored content
The Union presents a series of special webinar sessions, organised and paid for by our partners to showcase new science and new areas of work. All paid for sessions are reviewed for compliance with The Union’s mission and vision.
Past webinar
The twin epidemics of TB and COVID-19: challenges and controversies
Watch a recording of this webinar
This webinar is paid for and created by Oxford Immunotec.
